Dementia and Geriatric Cognitive Disorders

Dement Geriatr Cogn Disord

Log in to MyKarger to check if you already have access to this content.

Buy FullText & PDF Unlimited re-access via MyKarger Unrestricted printing, no saving restrictions for personal use read more

CHF 38.00 *
EUR 35.00 *
USD 39.00 *

Select

KAB

Buy a Karger Article Bundle (KAB) and profit from a discount!

If you would like to redeem your KAB credit, please log in.

Save over 20% compared to the individual article price.

Learn more

Access via DeepDyve Unlimited fulltext viewing Of this article Organize, annotate And mark up articles Printing And downloading restrictions apply

Select

Subscribe Access to all articles of the subscribed year(s) guaranteed for 5 years Unlimited re-access via Subscriber Login or MyKarger Unrestricted printing, no saving restrictions for personal use read more

Subcription rates

Select

* The final prices may differ from the prices shown due to specifics of VAT rules.

Article / Publication Details

First-Page Preview

Received: October 05, 2022
Accepted: October 20, 2022
Published online: December 12, 2022

Number of Print Pages: 6
Number of Figures: 0
Number of Tables: 0

ISSN: 1420-8008 (Print)
eISSN: 1421-9824 (Online)

For additional information: https://www.karger.com/DEM

Abstract

Introduction: Traumatic brain injury (TBI) has been associated with a greater risk of late-life dementia, including Alzheimer’s disease (AD), but only a few studies examined the relationship between residuals of blunt TBI and autopsy-proven AD. The objective of the present study was to examine the incidence of fully developed AD pathology after documented blunt TBI, and the frequency of residuals of blunt TBI in a series of cases with definite AD. Methods: Among a sample of 1,750 consecutive autopsy cases of elderly demented patients, those cases with residuals of blunt (closed) TBI and definite AD pathology were assessed, and among 933 individuals with autopsy-proven AD, those with residuals of blunt TBI were selected. Results: Among 190 autopsy cases with residuals of blunt TBI, 28 (14.7%; mean age 77.2 ± 10.6 years) revealed the pathological features of definite AD (Braak stage V or VI; ABC 3/3/3), while among 1,150 elderly controls (Braak stage < IV, mean age 77.3 ± 9.5 years), 160 (13.6%) showed residuals of blunt TBI. The second part of the study included 933 consecutive cases with definite AD (Braak stage V or VI; ABC 3/3/3, mean age 82.3 ± 8.4 years), in which 30 cases (3.3%; mean age 77.8 ± 10.7 years) showed morphological residuals of blunt TBI. Conclusion: The results of this retrospective study, on the one hand, did not support the idea that blunt TBI and its morphological residuals are responsible for the development of definite AD, whereas the second part of the study, showing morphological residuals of blunt TBI among 3.3% of definite AD cases were similar to the results in a clinical series who sustained moderate to severe TBI. Considering these conflicting results, further studies on the relationship between the severity and location of morphological residuals of blunt TBI and the development of AD pathology are warranted.

© 2022 S. Karger AG, Basel

References Agrawal S, Leurgans SE, James BD, Barnes LL, Mehta RI, Dams-O’Connor K, et al. Association of traumatic brain injury with and without loss of consciousness with neuropathologic outcomes in community-dwelling older persons. JAMA Netw Open. 2022;5(4):e229311. Brett BL, Gardner RC, Godbout J, Dams-O’Connor K, Keene CD. Traumatic brain injury and risk of neurodegenerative disorder. Biol Psychiatry. 2022;91(5):498–507. Gardner RC, Burke JF, Nettiksimmons J, Kaup A, Barnes DE, Yaffe K. Dementia risk after traumatic brain injury vs nonbrain trauma: the role of age and severity. JAMA Neurol. 2014;71(12):1490–7. Graham A, Livingston G, Purnell L, Huntley J. Mild traumatic brain injuries and future risk of developing Alzheimer’s disease: systematic review and meta-analysis. J Alzheimers Dis. 2022;87(3):969–79. Gu D, Ou S, Liu G. Traumatic brain injury and risk of dementia and Alzheimer’s disease: a systematic review and meta-analysis. Neuroepidemiology. 2022;56(1):4–16. Leung KK, Carr FM, Russell MJ, Bremault-Phillips S, Triscott JAC. Traumatic brain injuries among veterans and the risk of incident dementia: a systematic review & meta-analysis. Age Ageing. 2022:51(1):afab194. Li Y, Li Y, Li X, Zhang S, Zhao J, Zhu X. Head injury as a risk factor for dementia and Alzheimer’s disease: a systematic review and meta-analysis of 32 observational studies. PLoS One. 2017;12(1):e0169650. Mielke MM, Ransom JE, Mandrekar J, Turcano P, Savica R, Brown AW. Traumatic brain injury and risk of Alzheimer’s disease and related dementias in the population. J Alzheimers Dis. 2022;88(3):1049–59. Sivanandam TM, Thakur MK. Traumatic brain injury: a risk factor for Alzheimer’s disease. Neurosci Biobehav Rev. 2012;36(5):1376–81. Abner EL, Nelson PT, Schmitt FA, Browning SR, Fardo DW, Wan L, et al. Self-reported head injury and risk of late-life impairment and AD pathology in an AD center cohort. Dement Geriatr Cogn Disord. 2014;37(5–6):294–306. Jellinger KA. Head injury and dementia. Curr Opin Neurol. 2004;17(6):719–23. Tolppanen AM, Taipale H, Hartikainen S. Head or brain injuries and Alzheimer’s disease: a nested case-control register study. Alzheimer’s Dement. 2017;13(12):1371–9. Nordström A, Nordström P. Traumatic brain injury and the risk of dementia diagnosis: a nationwide cohort study. PLoS Med. 2018;15(1):e1002496. Lye TC, Shores EA. Traumatic brain injury as a risk factor for Alzheimer’s disease: a review. Neuropsychol Rev. 2000;10(2):115–29. Weiner MW, Harvey D, Landau SM, Veitch DP, Neylan TC, Grafman JH, et al. Traumatic brain injury and post-traumatic stress disorder are not associated with Alzheimer’s disease pathology measured with biomarkers. Alzheimers Dement. 2022. Launer LJ, Andersen K, Dewey ME, Letenneur L, Ott A, Amaducci LA, et al. Rates and risk factors for dementia and Alzheimer’s disease: results from EURODEM pooled analyses EURODEM Incidence Research Group and Work Groups. European Studies of Dementia. Neurology. 1999;52(1):78–84. Mehta KM, Ott A, Kalmijn S, Slooter AJ, van Duijn CM, Hofman A. Head trauma and risk of dementia and Alzheimer’s disease: the Rotterdam Study. Neurology. 1999;53(9):1959–62. Weiner MW, Harvey D, Hayes J, Landau SM, Aisen PS, Petersen RC, et al. Effects of traumatic brain injury and posttraumatic stress disorder on development of Alzheimer’s disease in Vietnam Veterans using the Alzheimer’s disease neuroimaging initiative: preliminary report. Alzheimers Dement (N Y). 2017;3(2):177–88. Crane PK, Gibbons LE, Dams-O’Connor K, Trittschuh E, Leverenz JB, Keene CD, et al. Association of traumatic brain injury with late-life neurodegenerative conditions and neuropathologic findings. JAMA Neurol. 2016;73:1062–9. Jellinger KA. Traumatic brain injury and Alzheimer’s disease neuropathology. Alzheimer’s Dement. 2019;15(9):1236–7. Sugarman MA, McKee AC, Stein TD, Tripodis Y, Besser LM, Martin B, et al. Failure to detect an association between self-reported traumatic brain injury and Alzheimer’s disease neuropathology and dementia. Alzheimer’s Dement. 2019;15(5):686–98. Iacono D, Raiciulescu S, Olsen C, Perl DP. Traumatic brain injury exposure lowers age of cognitive decline in ad and non-ad conditions. Front Neurol. 2021;12:573401. Mohamed AZ, Nestor PJ, Cumming P, Nasrallah FA. Traumatic brain injury fast-forwards Alzheimer’s pathology: evidence from amyloid positron emission tomorgraphy imaging. J Neurol. 2022;269(2):873–84. Schaffert J, LoBue C, White CL, Chiang HS, Didehbani N, Lacritz L, et al. Traumatic brain injury history is associated with an earlier age of dementia onset in autopsy-confirmed Alzheimer’s disease. Neuropsychology. 2018;32(4):410–6. Julien J, Joubert S, Ferland MC, Frenette LC, Boudreau-Duhaime MM, Malo-Véronneau L, et al. Association of traumatic brain injury and Alzheimer disease onset: a systematic review. Ann Phys Rehabil Med. 2017;60(5):347–56. LoBue C, Wadsworth H, Wilmoth K, Clem M, Hart J Jr, Womack KB, et al. Traumatic brain injury history is associated with earlier age of onset of Alzheimer disease. Clin Neuropsychol. 2017;31(1):85–98. Nemetz PN, Leibson C, Naessens JM, Beard M, Kokmen E, Annegers JF, et al. Traumatic brain injury and time to onset of Alzheimer’s disease: a population-based study. Am J Epidemiol. 1999;149(1):32–40. Plassman BL, Havlik RJ, Steffens DC, Helms MJ, Newman TN, Drosdick D, et al. Documented head injury in early adulthood and risk of Alzheimer’s disease and other dementias. Neurology. 2000;55(8):1158–66. Guo Z, Cupples LA, Kurz A, Auerbach SH, Volicer L, Chui H, et al. Head injury and the risk of AD in the MIRAGE study. Neurology. 2000;54(6):1316–23. Mazzeo AT, Beat A, Singh A, Bullock MR. The role of mitochondrial transition pore, and its modulation, in traumatic brain injury and delayed neurodegeneration after TBI. Exp Neurol. 2009;218(2):363–70. Puntambekar SS, Saber M, Lamb BT, Kokiko-Cochran ON. Cellular players that shape evolving pathology and neurodegeneration following traumatic brain injury. Brain Behav Immun. 2018;71:9–17. Becker RE, Kapogiannis D, Greig NH. Does traumatic brain injury hold the key to the Alzheimer’s disease puzzle? Alzheimer’sDement. 2018;14(4):431–43. Hicks AJ, Ponsford JL, Spitz G, Dore V, Krishnadas N, Roberts C, et al. β-amyloid and tau imaging in chronic traumatic brain injury: a cross-sectional study. Neurology. 2022;99(11):e1131–41. Mendez MF. What is the relationship of traumatic brain injury to dementia? J Alzheimers Dis. 2017;57(3):667–81. Shao F, Wang X, Wu H, Wu Q, Zhang J. Microglia and neuroinflammation: crucial pathological mechanisms in traumatic brain injury-induced neurodegeneration. Front Aging Neurosci. 2022;14:825086. Sharma HS, Muresanu DF, Castellani RJ, Nozari A, Lafuente JV, Buzoianu AD, et al. Alzheimer’s disease neuropathology is exacerbated following traumatic brain injury. Neuroprotection by co-administration of nanowired mesenchymal stem cells and cerebrolysin with monoclonal antibodies to amyloid beta peptide. Prog Brain Res. 2021;265:1–97. Srinivasan G, Brafman DA. The emergence of model systems to investigate the link between traumatic brain injury and Alzheimer's disease. Front Aging Neurosci. 2021;13:813544. Nicoll JA, Roberts GW, Graham DI. Apolipoprotein E epsilon 4 allele is associated with deposition of amyloid beta-protein following head injury. Nat Med. 1995;1(2):135–7. Horsburgh K, Cole GM, Yang F, Savage MJ, Greenberg BD, Gentleman SM, et al. β-Amyloid (Aβ)42(43), Aβ42, Aβ40 and apoE immunostaining of plaques in fatal head injury. Neuropathol Appl Neurobiol. 2000;26(2):124–32. Albayram O, Herbert MK, Kondo A, Tsai CY, Baxley S, Lian X, et al. Function and regulation of tau conformations in the development and treatment of traumatic brain injury and neurodegeneration. Cell Biosci. 2016;6:59. Geddes JF, Vowles GH, Nicoll JA, Revesz T. Neuronal cytoskeletal changes are an early consequence of repetitive head injury. Acta Neuropathol. 1999;98(2):171–8. Smith DH, Meaney DF. Axonal damage in traumatic brain injury. Neuroscientist. 2000;6:483–95. Rubenstein R, Chang B, Grinkina N, Drummond E, Davies P, Ruditzky M, et al. Tau phosphorylation induced by severe closed head traumatic brain injury is linked to the cellular prion protein. Acta Neuropathol Commun. 2017;5(1):30. Johnson VE, Stewart W, Smith DH. Widespread tau and amyloid-beta pathology many years after a single traumatic brain injury in humans. Brain Pathol. 2012;22(2):142–9. Johnson NH, de Rivero Vaccari JP, Bramlett HM, Keane RW, Dietrich WD. Inflammasome activation in traumatic brain injury and Alzheimer’s disease. Transl Res. 2022:S1931–5244(22)00201-8. Li L, Liang J, Fu H. An update on the association between traumatic brain injury and Alzheimer’s disease: focus on Tau pathology and synaptic dysfunction. Neurosci Biobehav Rev. 2021;120:372–86. Mohamed AZ, Cumming P, Nasrallah FA. Escalation of tau accumulation after a traumatic brain injury: findings from positron emission tomography. Brain Sci. 2022;12(7):876. Streubel-Gallasch L, Zysk M, Beretta C, Erlandsson A. Traumatic brain injury in the presence of A-beta pathology affects neuronal survival, glial activation and autophagy. Sci Rep. 2021;11(1):22982. Wu Z, Wang ZH, Liu X, Zhang Z, Gu X, Yu SP, et al. Traumatic brain injury triggers APP and Tau cleavage by delta-secretase, mediating Alzheimer’s disease pathology. Prog Neurobiol. 2020;185:101730. Johnson VE, Stewart W, Smith DH. Traumatic brain injury and amyloid-β pathology: a link to Alzheimer’s disease? Nat Rev Neurosci. 2010;11(5):361–70. Bird SM, Sohrabi HR, Sutton TA, Weinborn M, Rainey-Smith SR, Brown B, et al. Cerebral amyloid-β accumulation and deposition following traumatic brain injury--a narrative review and meta-analysis of animal studies. Neurosci Biobehav Rev. 2016;64:215–28. Bramlett HM, Dietrich WD. Long-term consequences of traumatic brain injury: current status of potential mechanisms of injury and neurological outcomes. J Neurotrauma. 2015;32(23):1834–48. Franzblau M, Gonzales-Portillo C, Gonzales-Portillo GS, Diamandis T, Borlongan MC, Tajiri N, et al. Vascular damage: a persisting pathology common to Alzheimer’s disease and traumatic brain injury. Med Hypotheses. 2013;81:842–5. Jellinger KA, Paulus W, Wrocklage C, Litvan I. Effects of closed traumatic brain injury and genetic factors on the development of Alzheimer’s disease. Eur J Neurol. 2001;8(6):707–10. Jellinger KA, Paulus W, Wrocklage C, Litvan I. Traumatic brain injury as a risk factor for Alzheimer disease. Comparison of two retrospective autopsy cohorts with evaluation of ApoE genotype. BMC Neurol. 2001;1:3. Kenney K, Iacono D, Edlow BL, Katz DI, Diaz-Arrastia R, Dams-O’Connor K, et al. Dementia after moderate-severe traumatic brain injury: coexistence of multiple proteinopathies. J Neuropathol Exp Neurol. 2018;77(1):50–63. Weiner MW, Crane PK, Montine TJ, Bennett DA, Veitch DP. Traumatic brain injury may not increase the risk of Alzheimer disease. Neurology. 2017;89(18):1923–5. Braak H, Alafuzoff I, Arzberger T, Kretzschmar H, Del Tredici K. Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry. Acta Neuropathol. 2006;112(4):389–404. Thal DR, Rub U, Orantes M, Braak H. Phases of A beta-deposition in the human brain and its relevance for the development of AD. Neurology. 2002;58(12):1791–800. Montine TJ, Phelps CH, Beach TG, Bigio EH, Cairns NJ, Dickson DW, et al. National Institute on aging-Alzheimer’s association guidelines for the neuropathologic assessment of Alzheimer’s disease: a practical approach. Acta Neuropathol. 2012;123:1–11. Wrocklage C, Bernatik J, Stefan H, Jellinger KA, Paulus W. Apolipoprotein E genotype in epilepsy and schizophrenia patients with cognitive deficits (Abstract). Acta Neuropathol. 1999;98:557. Corder EH, Lannfelt L, Bogdanovic N, Fratiglioni L, Mori H. The role of APOE polymorphisms in late-onset dementias. Cell Mol Life Sci. 1998;54(9):928–34. Harrington CR, Louwagie J, Rossau R, Vanmechelen E, Perry RH, Perry EK, et al. Influence of apolipoprotein E genotype on senile dementia of the Alzheimer and Lewy body types. Significance for etiological theories of Alzheimer’s disease. Am J Pathol. 1994;145(6):1472–84. Rebeck GW, Perls TT, West HL, Sodhi P, Lipsitz LA, Hyman BT. Reduced apolipoprotein epsilon 4 allele frequency in the oldest old Alzheimer’s patients and cognitively normal individuals. Neurology. 1994;44(8):1513–6. Mendez MF, Paholpak P, Lin A, Zhang JY, Teng E. Prevalence of traumatic brain injury in early versus late-onset Alzheimer’s disease. J Alzheimers Dis. 2015;47(4):985–93. Tripodis Y, Alosco ML, Zirogiannis N, Gavett BE, Chaisson C, Martin B, et al. The effect of traumatic brain injury history with loss of consciousness on rate of cognitive decline among older adults with normal cognition and Alzheimer’s disease dementia. J Alzheimers Dis. 2017;59(1):251–63. Johnson VE, Stewart JE, Begbie FD, Trojanowski JQ, Smith DH, Stewart W. Inflammation and white matter degeneration persist for years after a single traumatic brain injury. Brain. 2013;136(1):28–42. Schofield PW, Tang M, Marder K, Bell K, Dooneief G, Chun M, et al. Alzheimer’s disease after remote head injury: an incidence study. J Neurol Neurosurg Psychiatry. 1997;62(2):119–24. Zhang L, Yang W, Li X, Dove A, Qi X, Pan KY, et al. Association of life-course traumatic brain injury with dementia risk: a nationwide twin study. Alzheimers Dement. 2022. van Amerongen S, Caton DK, Pijnenburg YAL, Scheltens P, Vijverberg EGB. Clinical features of patients with Alzheimer’s disease and a history of traumatic brain injury. Dement Geriatr Cogn Dis Extra. 2022;12(3):122–30. Sabo T, Lomnitski L, Nyska A, Beni S, Maronpot RR, Shohami E, et al. Susceptibility of transgenic mice expressing human apolipoprotein E to closed head injury: the allele E3 is neuroprotective whereas E4 increases fatalities. Neuroscience. 2000;101(4):879–84. Van Den Heuvel C, Thornton E, Vink R. Traumatic brain injury and Alzheimer’s disease: a review. Prog Brain Res. 2007;161:303–16. Article / Publication Details

First-Page Preview

Received: October 05, 2022
Accepted: October 20, 2022
Published online: December 12, 2022

Number of Print Pages: 6
Number of Figures: 0
Number of Tables: 0

ISSN: 1420-8008 (Print)
eISSN: 1421-9824 (Online)

For additional information: https://www.karger.com/DEM

Copyright / Drug Dosage / Disclaimer Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.